{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:19:42Z","timestamp":1762251582535,"version":"3.37.3"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1124\/dmd.109.030130","type":"journal-article","created":{"date-parts":[[2010,2,3]],"date-time":"2010-02-03T03:48:05Z","timestamp":1265168885000},"page":"879-886","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["A Humanized UGT1 Mouse Model Expressing the UGT1A1*28 Allele for Assessing Drug Clearance by UGT1A1-Dependent Glucuronidation"],"prefix":"10.1016","volume":"38","author":[{"given":"Hongliang","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nghia","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Peterkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Sun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Hotz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deirdre Beaton","family":"La Placa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert H.","family":"Tukey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey C.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.109.030130_bib1","first-page":"258","article-title":"UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy","volume":"9","author":"Ando","year":"2007","journal-title":"Curr Opin Mol Ther"},{"key":"10.1124\/dmd.109.030130_bib2","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3109\/00498250903188985","article-title":"Studies on induction of lamotrigine metabolism in transgenic UGT1 mice","volume":"39","author":"Argikar","year":"2009","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.109.030130_bib3","first-page":"61","article-title":"Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research?","volume":"12","author":"Beaumont","year":"2009","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1124\/dmd.109.030130_bib4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0168-8278(02)00359-8","article-title":"Inherited disorders of bilirubin metabolism","volume":"38","author":"Bosma","year":"2003","journal-title":"J Hepatol"},{"key":"10.1124\/dmd.109.030130_bib5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF03190588","article-title":"Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1\/2 be predicted from in-vivo rat data?","volume":"29","author":"Caldwell","year":"2004","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.109.030130_bib6","doi-asserted-by":"crossref","first-page":"37547","DOI":"10.1074\/jbc.M506683200","article-title":"Tissue-specific, inducible, and hormonal control of the human UDP-glucuronosyltransferase-1 (UGT1) locus","volume":"280","author":"Chen","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.109.030130_bib7","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1124\/jpet.108.141242","article-title":"Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment","volume":"327","author":"Cheung","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.109.030130_bib8","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0022-3565(24)36601-7","article-title":"Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats","volume":"281","author":"Chu","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.109.030130_bib9","first-page":"73","article-title":"The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268)","volume":"26","author":"Coffman","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.030130_bib10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0076-6879(05)00007-8","article-title":"Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases","volume":"400","author":"Court","year":"2005","journal-title":"Methods Enzymol"},{"key":"10.1124\/dmd.109.030130_bib11","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1124\/dmd.107.015644","article-title":"Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs","volume":"35","author":"De Buck","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.030130_bib12","first-page":"48","article-title":"Use of cloned and expressed human UDP-glucuronosyltransferases for the assessment of human drug conjugation and identification of potential drug interactions","volume":"29","author":"Ethell","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.030130_bib13","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1158\/1055-9965.EPI-03-0070","volume":"13","author":"Fang","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1124\/dmd.109.030130_bib14","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1124\/dmd.107.016402","article-title":"Interactions between human UGT1A1, UGT1A4, and UGT1A6 affect their enzymatic activities","volume":"35","author":"Fujiwara","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.030130_bib15","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/mol.62.3.608","article-title":"Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38)","volume":"62","author":"Gagn\u00e9","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.109.030130_bib16","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1124\/dmd.32.3.314","article-title":"Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia)","volume":"32","author":"Ghosal","year":"2004","journal-title":"Drug Metab Dispos"},{"year":"1996","series-title":"Guide for the Care and Use of Laboratory Animals","key":"10.1124\/dmd.109.030130_bib17"},{"key":"10.1124\/dmd.109.030130_bib18","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2133\/dmpk.22.367","article-title":"Protein-protein interactions between rat hepatic cytochromes P450 (P450s) and UDP-glucuronosyltransferases (UGTs): evidence for the functionally active UGT in P450-UGT complex","volume":"22","author":"Ishii","year":"2007","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.109.030130_bib19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/sj.tpj.6500072","article-title":"UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity","volume":"2","author":"Iyer","year":"2002","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/dmd.109.030130_bib20","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0009-9236(99)70078-0","article-title":"Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism","volume":"65","author":"Iyer","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.109.030130_bib21","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1172\/JCI915","article-title":"Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes","volume":"101","author":"Iyer","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1124\/dmd.109.030130_bib22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1124\/dmd.108.023853","article-title":"Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes","volume":"37","author":"Kilford","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.030130_bib23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2174\/138920008784746355","article-title":"Applications and limitations of genetically modified mouse models in drug discovery and development","volume":"9","author":"Lin","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.109.030130_bib24","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.bcp.2005.12.019","article-title":"In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises","volume":"71","author":"Miners","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.109.030130_bib25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3109\/03602530903210716","article-title":"The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential","volume":"42","author":"Miners","year":"2010","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.109.030130_bib26","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0300-483X(02)00449-3","article-title":"Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance","volume":"181\u2013182","author":"Miners","year":"2002","journal-title":"Toxicology"},{"key":"10.1124\/dmd.109.030130_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.44.101802.121546","article-title":"Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches","volume":"44","author":"Miners","year":"2004","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.109.030130_bib28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/03602530600739835","article-title":"Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan","volume":"38","author":"Nagar","year":"2006","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.109.030130_bib29","doi-asserted-by":"crossref","first-page":"7901","DOI":"10.1074\/jbc.M709244200","article-title":"Disruption of the ugt1 locus in mice resembles human Crigler-Najjar type I disease","volume":"283","author":"Nguyen","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.109.030130_bib30","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1200\/JCO.2006.07.3031","article-title":"Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy","volume":"24","author":"O\u2019Dwyer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.109.030130_bib31","first-page":"1080","article-title":"[Role of UGT1A1*28 and UGT1A1*6 for irinotecan-induced adverse drug reaction]","volume":"35","author":"Onoue","year":"2008","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1124\/dmd.109.030130_bib32","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1074\/jbc.M609417200","article-title":"Oligomerization of the UDP-glucuronosyltransferase 1A proteins: homo- and heterodimerization analysis by fluorescence resonance energy transfer and co-immunoprecipitation","volume":"282","author":"Opera\u00f1a","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.109.030130_bib33","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2125.2007.02923.x","article-title":"Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes","volume":"64","author":"Peterkin","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.109.030130_bib34","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.021105","article-title":"The \u201calbumin effect\u201d and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities","volume":"36","author":"Rowland","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.030130_bib35","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1124\/dmd.31.6.762","article-title":"The effect of incubation conditions on the enzyme kinetics of UDP-glucuronosyltransferases","volume":"31","author":"Soars","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.030130_bib36","doi-asserted-by":"crossref","first-page":"36164","DOI":"10.1074\/jbc.M002180200","article-title":"Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine","volume":"275","author":"Strassburg","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.109.030130_bib37","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1248\/bpb.28.2026","article-title":"Modulation of UDP-glucuronosyltransferase 2B7 function by cytochrome P450s in vitro: differential effects of CYP1A2, CYP2C9 and CYP3A4","volume":"28","author":"Takeda","year":"2005","journal-title":"Biol Pharm Bull"},{"key":"10.1124\/dmd.109.030130_bib38","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1146\/annurev.pharmtox.40.1.581","article-title":"Human UDP-glucuronosyltransferases: metabolism, expression, and disease","volume":"40","author":"Tukey","year":"2000","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.109.030130_bib39","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1124\/mol.62.3.446","article-title":"Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity","volume":"62","author":"Tukey","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.109.030130_bib40","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1097\/FPC.0b013e328256b1b6","article-title":"Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates","volume":"17","author":"Udomuksorn","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.109.030130_bib41","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1124\/dmd.107.017806","article-title":"Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism","volume":"35","author":"Zhang","year":"2007","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624023651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624023651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.109.030130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:48:59Z","timestamp":1739897339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624023651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S0090955624023651"],"URL":"https:\/\/doi.org\/10.1124\/dmd.109.030130","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2010,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Humanized UGT1 Mouse Model Expressing the UGT1A1*28 Allele for Assessing Drug Clearance by UGT1A1-Dependent Glucuronidation","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.109.030130","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2010 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}